個案總覽
依發行單位、學門或關鍵字,找到適合的教學個案。
-
TransDigm's Acquisition and Integration of Arkwin Industries
In May 2013, TransDigm, a company that manufactured a wide range of highly engineered aerospace parts for both military and civilian aircraft, announced it was buying Arkwin Industries for $286 million in cash (3 times Arkwin's sales of $91 million). Having acquired more than 40 companies in the past 20 years, TransDigm was an experienced acquirer with a unique business model focused exclusively on value creation. This case describes TransDigm's acquisition, integration, and talent development processes as well as the changes made at Arkwin over the following three years. It serves as a complement to the TransDigm in 2017 case (HBS #720-422). Whereas the TransDigm case provides an overview of the company, its history, its value creation strategy, and its financial performance, the Arkwin Industries case provides a deep dive into a single transaction as a way to illustrate TransDigm's value creation strategy in practice. That strategy consisted of three parts-value-based pricing, cost reductions, and new product development-and had the goal of doubling a target firm's operating margins and cash flows within five years. -
TransDigm in 2017: The Beginning of the End or the End of the Beginning?
TransDigm was a highly acquisitive company that manufactured a wide range of highly engineered aerospace parts for both military and commercial customers. Over the ten years ending in 2016, its stock price had increase ten times, and both EBITDA and revenues had grown at compound annual rates in excess of 20%. But in early 2017, investors, customers, and government officials began to question the implementation, sustainability, and ethics of the firm's unique value creation strategy. That strategy consisted of three parts: value-based pricing, cost reductions, and new product development. In the short term, CEO Nick Howley had to decide whether to respond to the barrage of criticism; in the longer term, he had to decide whether to change the firm's highly successful strategy. -
TransDigm in 2017: The Beginning of the End or the End of the Beginning?, Spreadsheet Supplement
Spreadsheet supplement for case 720422. -
TiVo 2020
This short cases provides an update on TiVo from 2016-2020. The case covers TiVo merger with Rovi, the turnover of several CEOs, and struggles on how to reposition its product business (the digital video recorder). -
Apple Inc. in 2020
After a decade as CEO, Tim Cook is facing one of his biggest strategic transitions of his tenure. While Apple had performed spectacularly well under Cook, Apple's core business was maturing. Sales of iPhones, iPads, and Macs were flat or down. However, Apple's new hardware-Apple Watch and Airpods-as well as services were growing rapidly. This case explores Apple's history and Cook's strategic options for driving new hardware and services into Apple's mainstream in the next decade. -
Intellectual Ventures Update 2020
After raising $6 billion and buying 60,000 patents, Intellectual Venture was confronted with a changing legal environment. A number of important legal decision, including the Supreme Court's so-called "Alice" decision, IV had to shift strategy. IV sold off a substantial portion of its IP portfolio, and refocused its efforts on trying to innovate, using its acquired technologies. -
MoviePass: The "Get Big Fast" Strategy, Spreadsheet Supplement
Spreadsheet supplement to case 719455. -
Gillette: Cutting Prices to Regain Share, Spreadsheet Supplement
Spreadsheet supplement for case 720378. -
United Technologies: Are the Parts Worth More Than the Whole?, Spreadsheet Supplement
Spreadsheet supplement for case 220018. -
United Technologies: Are the Parts Worth More Than the Whole?
After spending more than 50 years creating a diversified industrial conglomerate that Fortune Magazine described as "arguably the most profitable conglomerate in America" in 2014, UTC's CEO Greg Hayes was under pressure from activist investors (Dan Loeb and Bill Ackman) to break the company into three standalone businesses in the spring of 2018. The activists claimed that a breakup would create at least $20 billion of incremental value (on top of a current market value of approximately $100 billion) and possibly a lot more. Hayes must decide whether a breakup makes sense-will it create value and, if so, how much value and why? What factors determine whether a conglomerate trades at a discount or a premium, and how big are those discounts and premiums likely to be? -
Gillette: Cutting Prices to Regain Share
After losing market share to low-priced competitors such as Harry's and Dollar Shave Club for several years, Gillette decided to fight back by launching new products and increasing advertising. When these efforts failed to stem the losses, Gillette decided to cut the prices on its razors and blades in April 2017. Bonnie Herzog, an equity analyst at Wells Fargo, must assess how the recently announced price cuts are likely to affect Gillette's earnings and its parent company's earnings (Procter & Gamble owns Gillette). As part of her analysis, Herzog must estimate the price elasticity of demand for Gillette's razors and blades. The case contains scanner data which allows students to calculate both price elasticities for a sample of Gillette products, and sufficient data to estimate the financial impact. -
Impax Laboratories: Executing Accretive Acquisitions (A), Spreadsheet Supplement
Spreadsheet supplement to case 220030. -
Impax Laboratories: Executing Accretive Acquisitions (B)
IExplores events after Impax announced the acquisition of a portfolio of generic pharmaceutical products from Teva in June 2016. -
Impax Laboratories: Executing Accretive Acquisitions (A)
Impax Laboratories was a technology-based pharmaceutical company that used a "dual platform" strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the early morning of June 21, 2016, the firm issued a press release announcing it was buying a portfolio of generic drugs from Teva for $586 million in cash. The leadership team (CEO, CFO, and Head of Investor Relations) was now preparing for a conference call with analysts and investors to describe the deal's acquisition price, strategic rationale, and financial impact. Like its first major acquisition-the acquisition of Tower Holdings in 2014 for $700 million-the Teva acquisition was expected to be immediately accretive (i.e., the firm's expected earnings per share in 2016 would increase). Was the leadership team ready to answer the full range of questions investors might ask and to explain the deal's strategic rationale and financial implications in compelling ways? And would investors react as favorably to the Teva announcement as they had when Impax announced the Tower Holdings acquisition-Impax closed up 12% that day? -
Fixing Facebook: Fake News, Privacy, and Platform Governance
Mark Zuckerberg founded Facebook based on the idea that connecting people was a fundamentally good thing-and a way to turn a handsome profit. But from the beginning, Facebook received criticism both for how it handled user privacy and how it curated user-generated content. These two issues coalesced in the aftermath of the 2016 United States presidential election, after Facebook's role in the spread of political misinformation and the leak of Facebook user data to political consulting firms began to receive significant media coverage. In 2019, Facebook announced it was shifting to a "digital living room" model that would focus more on private, encrypted conversations and less on sharing viral content. Several important questions remained. Would the digital living room ease users' privacy concerns? Would Facebook still be able to effectively curate content? Would its advertising model still work? Or were financial success and good governance mutually exclusive? This case explores the parameters of governing an internet-based platform. -
Elon Musk's Big Bets Update, 2019
This short case provides an update to Elon Musk's strategy and tactical moves with Tesla, Solar City, and SpaceX from 2016-2019. -
Mobileye Update, 2019
Mobileye was an Israeli company, officially headquartered in The Netherlands, which was a Tier 2 supplier to the global automobile industry. This short case updates Mobileye's business performance and strategy, following the acquisition by Intel in 2017. -
Walmart Update, 2019
In 2019 Walmart was still the world's largest company, with over $500 billion in annual revenue and operations around the world. Although it had mostly vanquished its rival discount retailers in the U.S., it was struggling to find the right growth strategy. Facing a mature U.S. market, it had looked to ecommerce and international sales as an engine of growth. Walmart leadership also faced intense competition from dominant online retailer Amazon. In such a competitive environment, how should Walmart respond to the reality that its traditional strengths no longer guaranteed robust growth? -
MoviePass: The "Get Big Fast" Strategy
In August 2017, MoviePass dramatically lowered its subscription price from $50 per month to just $10 for up to one movie per day. The idea was to rapidly scale the business to the point where it could generate incremental revenue streams from related businesses (e.g., a share of ticket and concession revenues from theaters, advertising revenue from movie studios; and revenue from ride-sharing companies). Within two days, Moviepass had gotten 150k new subscribers; within six months, it had more than 2 million. But as of February 2018, the company faced three challenges: theaters were resisting the concept, investors were shorting the stock in record numbers as losses mounted, and competitors were beginning to appear. Could CEO Lowe convince investors that the company was viable and it could, indeed, monetize the growing subscriber base? At the same time, Lowe had to decide whether to raise subscription prices to cover the growing losses or keep prices low to grow the subscriber base as quickly as possible. -
The a2 Milk Company
The a2 Milk Company (a2MC) became the most valuable company listed on the New Zealand stock exchange in 2018 by capitalizing on a biochemical discovery related to the protein composition of cow's milk. Because many people find the A1 protein difficult to digest, and that protein may be related to other health problems (e.g., diabetes), a2MC sells dairy products containing the A2 protein only primarily in Australia and China. With sales of NZ$730 million in 2017 and a desire to grow, a2MC formed a strategic relationship with Fonterra, the world's sixth largest dairy company, in February 2018. But one month later, Nestle, the world's largest dairy company, confirmed that it had begun selling A2 infant formula in China, and people speculated that it would start selling A2 products in Australia and New Zealand later in the year. a2MC's retiring CEO Geoffrey Babidge and newly appointed CEO Janyne Hrdlicka must decide how to respond to Nestle's entry. Can this successful entrant become an incumbent with a sustainable competitive advantage?